Industry

China Beauty & Personal Care - the arena Yatsen plays in

China is the world's second-largest beauty market, generating roughly ¥550-700 billion of retail sales a year and growing in the mid-single digits. Money in this industry is made not at the factory (where contract manufacturers like Cosmax, Intercos and Kolmar take the unit-economics) but in the brand, content, channel and shelf-position layer: gross margins routinely run 70-80% across the listed peer set, but marketing and traffic costs frequently eat 50-70% of revenue, so the entire game is whether brand equity and customer repeat outpace the cost of buying attention on Tmall, Douyin and RedNote. The newcomer's most common mistake is to read "78% gross margin" as a moat — for digital-native brands like Yatsen the gross margin is a budget for marketing, not a profit line. Two cycles run inside this industry simultaneously: a slow structural shift from foreign multinationals to Chinese domestic brands (local share rose from 43% in 2015 to ~57% in 2024 per Xinhua / Frost & Sullivan; cited as ~60% in 2026), and a faster mix shift from cyclical color cosmetics into stickier, higher-margin skincare that has reshaped the FY2025 P&L of every listed Chinese player.

Takeaway: profits cluster at the brand layer and at the digital-platform layer. Manufacturers are largely commoditised; retailers and KOLs siphon a steady toll.

1. Industry in One Page

China is one of two giant national beauty profit pools (the other being the United States) and the only one where domestic brands are taking share from incumbent multinationals at scale. Three structural facts define the rest of this report:

• Demand is large, growing in single digits, and underpenetrated. Industry trackers tied to National Bureau of Statistics data put FY2025 China beauty retail growth at roughly +5% for the year and ~+8% in Q4. Per-capita beauty spend in China was around US$28 at IPO-time (2020 Yatsen prospectus, citing Frost & Sullivan) versus ~US$153 in South Korea and ~US$97 in the US — a gap that drives the long-run growth thesis.
• Skincare is roughly four times the size of color cosmetics in China, and structurally more attractive (higher gross margins, higher repeat rates, higher willingness to pay for clinical claims). This is why every credible Chinese beauty group — Yatsen, Proya, Yunnan Botanee, Mao Geping — has tilted its portfolio toward skincare since 2022.
• The mix between Chinese and foreign brands has flipped over a decade, pressuring listed multinationals: Estée Lauder's revenue fell from US$15.6B (FY24, ended June 30, 2024) to US$14.3B (FY25, ended June 30, 2025) with a US$1.13B reported net loss; Coty's FY25 (ended June 30, 2025) results swung to net loss; Shiseido trades on a 207× trailing P/E. The Chinese consumer is voting with her wallet for local, scientifically-credentialed brands.

What a newcomer usually gets wrong: assuming all "beauty" is one market. Mass color cosmetics, prestige skincare, dermo-cosmetics, derm-clinic-adjacent products, fragrance, and tools each have different demand drivers, channel mixes, pricing logic and competitor sets. Yatsen sits across most of them.

2. How This Industry Makes Money

The revenue model is simple: sell a small physical good (lipstick ¥80-180, serum ¥200-600, prestige cream ¥800-2,000+) at a multiple of manufacturing cost. The complication is everything that sits between the bottle and the consumer.

Takeaway: gross margin is similar across listed beauty brands (70-80%). What separates a profitable from an unprofitable beauty company is what happens below the gross profit line. Yatsen's 66% marketing intensity is roughly double Estee Lauder's 32% and almost three times e.l.f. Beauty's 24%.

Capital intensity is low; working-capital and marketing intensity are not. Listed Chinese beauty brands typically run capex at under 2% of revenue and carry slim PP&E because manufacturing is outsourced. The cash drain is inventory, payables to platforms, and especially the upfront marketing spend to launch a new SKU or sustain a hero product through the next 6.18 / Double 11 / Double 12 promotional cycle.

Pricing units to know. Color cosmetics retail at ¥30-200; mass skincare at ¥80-300; premium skincare at ¥300-1,000; prestige skincare and clinical/medical-aesthetic adjacencies at ¥800-3,000+. Discount discipline — i.e. not slashing list price during 6.18 or Double 11 — is the difference between a brand-equity strategy and a doom-loop of permanent markdowns. Yatsen attributes 1,020 bps of gross-margin expansion since 2022 (68.0% → 78.2%) to "stricter pricing and discount policies."

Where bargaining power sits. Upstream (ingredients, packaging, ODM) is fragmented but has been consolidating around four global majors (Cosmax, Intercos, Kolmar, plus regional captives). Downstream (platforms and KOLs) is highly concentrated — Tmall and Douyin together intermediate the majority of online beauty GMV, and top livestream anchors set commercial terms during peak shopping festivals. A standalone digital-native brand without platform alternatives is structurally a price-taker on traffic.

3. Demand, Supply, and the Cycle

Beauty demand is procyclical but more resilient than discretionary apparel — lipstick survives recessions, prestige skincare gets traded down rather than abandoned. Supply is rarely constrained; the binding constraints are attention and shelf-space (digital, KOL, retail) not factories.

Where downturns hit first. Color cosmetics is the canary: it is more discretionary, more impulsive, and more correlated with workplace and event consumption. Yatsen's own 2021 transcripts flagged a "significant deceleration in general consumer and color cosmetics spending" in 3Q21 even as the broader industry was still printing positive growth; the same brand's color cosmetics sales fell 9.1% in Q4 2025 while skincare was up 51.9%. Skincare is the next layer to crack, but only after two or three quarters of trading down within the category.

Takeaway: the post-COVID rebound in 2021 was anomalous; "normal" growth is in the 5-10% range, with a downturn in 2022 driven by lockdowns and a softer 2024. Q2 / Q4 of every year carry the majority of full-year volume because of 6.18 and Double 11.

4. Competitive Structure

The Chinese beauty market is moderately concentrated globally but locally fragmented: a handful of Western multinationals dominate prestige skincare while dozens of Chinese mass/color brands and emerging skincare specialists compete in the mass and mid-tier. Premium skincare is the strategic prize because economics there are best and incumbents (Estee Lauder, L'Oreal) are visibly losing ground.

Takeaway: the listed Chinese beauty peer set trades on a wide spread — Yatsen at ~0.3× EV/Revenue (loss-making, scale-deficient) to Mao Geping at 5.4× (profitable, prestige). What earns the multiple is proven profitability + skincare mix, not just China exposure.

5. Regulation, Technology, and Rules of the Game

China's beauty industry runs on a regulatory regime that has tightened sharply since 2021 — to the advantage of well-funded, R&D-credible incumbents and to the disadvantage of the long-tail of unregistered Douyin micro-brands. Anything making an efficacy claim (whitening, sunscreen, anti-aging, anti-hair-loss, freckle removal) is now a "special cosmetic" requiring NMPA registration, not just filing.

The investor implication. Regulation has raised the operating cost of being a beauty brand in China by perhaps 200-400 bps of revenue (compliance staff, ingredient testing, NMPA filings, platform-side audits) and has lengthened time-to-market for special cosmetics by 6-12 months. That hurts new entrants more than incumbents, partially offsetting the threat of Douyin-driven micro-brand fragmentation. For investors, the regulatory tightening is mildly moat-positive for listed scale brands with in-house R&D and regulatory teams — including Yatsen.

Technology is changing economics. Two shifts matter: (1) AI-assisted formulation and ingredient discovery is starting to shorten the lab-to-shelf cycle, which favours brands that have built data platforms; (2) the rise of medical-aesthetics and clinic-adjacent product lines (peptides, exosomes, mandelic acid) is creating a new mid-prestige category that bypasses both mass-market price-fighting and prestige-brand barriers.

6. The Metrics Professionals Watch

Takeaway: Yatsen has the highest gross margin and highest R&D intensity in the peer set, but also the highest marketing intensity. The narrowing of marketing intensity — not gross margin — is the single most important number to watch in coming quarters.

7. Where Yatsen Holding Limited Fits

8. What to Watch First